Swedish Orphan Biovitrum AB
SOBI
Rang in Aktien
#1383
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Aktienkurs
$45.40
Marktkapitalisierung
$15.78B
Veränderung (1 Tag)
-1.92%
Veränderung (1 Jahr)
35.18%
Land
SE
Handel Swedish Orphan Biovitrum AB (SOBI)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Swedish Orphan Biovitrum AB (SOBI)
Anzahl der ausstehenden Aktien zum October 2026: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Swedish Orphan Biovitrum AB beträgt die aktuelle Anzahl der ausstehenden Aktien 0. Am Ende von October 2026 hatte das Unternehmen 0 ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Swedish Orphan Biovitrum AB (SOBI) von 2002 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2025 | 344.30M | 0.75% |
| 2024 | 341.73M | 5.91% |
| 2023 | 322.66M | 4.26% |
| 2022 | 309.48M | 0.19% |
| 2021 | 308.90M | 0.13% |
| 2020 | 308.49M | 0.69% |
| 2019 | 306.38M | 13.22% |
| 2018 | 270.60M | 0.59% |
| 2017 | 269.02M | 0.25% |
| 2016 | 268.36M | 0.41% |
| 2015 | 267.28M | 0.79% |
| 2014 | 265.18M | -0.03% |
| 2013 | 265.27M | 0.01% |
| 2012 | 265.23M | 9.54% |
| 2011 | 242.12M | 21.83% |
| 2010 | 198.74M | 252.27% |
| 2009 | 56.42M | -49.59% |
| 2008 | 111.91M | 9.91% |
| 2007 | 101.82M | -1.51% |
| 2006 | 103.39M | 1.53% |
| 2005 | 101.82M | 0.00% |
| 2004 | 101.82M | 0.00% |
| 2003 | 101.82M | 0.00% |
| 2002 | 101.82M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 445.06M | - |
US
|
|
| - | - |
FR
|
|
| 105.38M | - |
US
|
|
| - | - |
IT
|
|
| 18.05B | - |
HK
|
